A large-scale study from the Penn Medicine BioBank demonstrates that polygenic risk scores for hypertrophic and dilated cardiomyopathies act as bidirectional modifiers, influencing the clinical expression of rare pathogenic variants and offering a new paradigm for cardiovascular risk stratification.